Pro-inflammatory cytokines such as Interferon-α, Interleukin-2, TNF-α, TGF-β et al. can contribute to cancer immunotherapy, acting on every phase of the cancer immunity cycle (Chen and Mellman, 2017). This evidence concerns the gene TGFB1 and cancer.